Stay updated on Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial
Sign up to get notified when there's something new on the Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial page.

Latest updates to the Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2 on the page, indicating a minor version change. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check21 days agoChange DetectedRevision: v3.3.1 replaces the previous v3.2.0 label on the page.SummaryDifference0.1%

- Check29 days agoChange DetectedRemoved the government funding status notice warning about potential delays and outdated information on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check43 days agoChange DetectedThe update is non-substantive: the Study Record Dates last update posted date is 2025-05-14; core content such as eligibility, outcomes, and locations remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check71 days agoChange Detected- Updated operating-status notice and new version tag (v3.2.0) added; old version tag (v3.1.0) removed. The page now provides current status guidance and a newer software/document version.SummaryDifference2%

- Check79 days agoChange DetectedUpdated the page revision from v3.0.2 to v3.1.0, indicating a new software release or document update. No other substantive content changes are indicated.SummaryDifference0.1%

Stay in the know with updates to Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial page.